Immatics Stock Performance

IMTX -  USA Stock  

USD 9.53  0.27  2.76%

The company retains a Market Volatility (i.e., Beta) of 0.4474, which attests to possible diversification benefits within a given portfolio. Let's try to break down what Immatics's beta means in this case. As returns on the market increase, Immatics returns are expected to increase less than the market. However, during the bear market, the loss on holding Immatics will be expected to be smaller as well. Even though it is essential to pay attention to Immatics NV current price history, it is always good to be careful when utilizing equity current price movements. Our philosophy towards determining any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Immatics NV exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Immatics NV has an expected return of -0.6%. Please be advised to check out Immatics maximum drawdown, as well as the relationship between the skewness and day typical price to decide if Immatics NV performance from the past will be repeated at some point in the near future.

Immatics Stock Performance 

 
Refresh
Immatics Performance
0 of 100
Over the last 90 days Immatics NV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2022. The current disturbance may also be a sign of long term up-swing for the company investors. ...more

Immatics Price Channel

Quick Ratio1.65
Fifty Two Week Low9.46
Target High Price31.94
Fifty Two Week High18.42
Target Low Price18.96

Immatics Relative Risk vs. Return Landscape

If you would invest  1,433  in Immatics NV on October 29, 2021 and sell it today you would lose (480.00)  from holding Immatics NV or give up 33.5% of portfolio value over 90 days. Immatics NV is currently does not generate positive expected returns and assumes 3.3401% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Immatics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Immatics is expected to under-perform the market. In addition to that, the company is 3.96 times more volatile than its market benchmark. It trades about -0.18 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.09 per unit of volatility.

Immatics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Immatics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immatics NV, and traders can use it to determine the average amount a Immatics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1796

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsIMTX
Estimated Market Risk
 3.34
  actual daily
 
 28 %
of total potential
 
2828
Expected Return
 -0.6
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.18
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Immatics is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immatics by adding it to a well-diversified portfolio.

About Immatics Performance

To evaluate Immatics NV Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Immatics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Immatics Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Immatics NV stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Immatics's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Effect of Exchange Rate Changes on Cash-1.9 M-2 M
Return on Average Assets(0.97) (1.05) 
Return on Average Equity(5.24) (5.38) 
Return on Invested Capital(16.95) (17.39) 
Return on Sales(7.40) (7.98) 
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed andor refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The companys TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications Amgen Inc. and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tbingen, Germany.

Things to note about Immatics NV

Checking the ongoing alerts about Immatics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immatics NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Immatics Alerts

Equity Alerts and Improvement Suggestions

Immatics NV generated a negative expected return over the last 90 days
Immatics NV has high historical volatility and very poor performance
The company reported the previous year's revenue of 28.48 M. Net Loss for the year was (112.29 M) with loss before overhead, payroll, taxes, and interest of (35.83 M).
Immatics NV currently holds about 173.21 M in cash with (80.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.75.
Immatics NV has a frail financial position based on the latest SEC disclosures
Roughly 33.0% of the company shares are held by company insiders
Please see Risk vs Return Analysis. Note that the Immatics NV information on this page should be used as a complementary analysis to other Immatics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Immatics Stock analysis

When running Immatics NV price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immatics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.